XSC
RLMD icon

X-Square Capital’s Relmada Therapeutics RLMD Stock Holding History

X-Square Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$692K Buy
+100,000
New +$699K 0.18% 115

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

X-Square Capital's RLMD Position: Q2 2026 in Review

X-Square Capital opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 100,000 shares worth $692K. The stake represents 0.18% of the portfolio and ranks #115 among its holdings.

126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • X-Square Capital held 100,000 shares of Relmada Therapeutics worth $692K as of Q2 2026.
  • Relmada Therapeutics was a new X-Square Capital position in Q2 2026.
  • Relmada Therapeutics made up 0.18% of X-Square Capital's portfolio in Q2 2026, its #115 holding.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on X-Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.